Eric Angevin

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Brain Metastases

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Solange Peters, Eric Angevin, Teresa Alonso Gordoa, Kristoffer Staal Rohrberg, Ignacio Melero Bermejo, Begona Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christiane Neumann, Barbara Leutgeb, Pavel Pisa, Eva Rossmann, José Saro, Pablo Umaña, Jehad Charo, Volker Teichgräber, Neeltje Steeghs
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Solange Peters, Eric Angevin, Teresa Alonso Gordoa, Kristoffer Staal Rohrberg, Ignacio Melero Bermejo, Begona Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christiane Neumann, Barbara Leutgeb, Pavel Pisa, Eva Rossmann, José Saro, Pablo Umaña, Jehad Charo, Volker Teichgräber, Neeltje Steeghs
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Melinda A Pruis, Matthew G Krebs, Ruth Plummer, Filip Yves Francine De Vos, Eric Angevin, Hans Prenen, Martin D Forster, Glen Clack, Annegret Van der Aa, Marc Tjwa, Ellen Jansen, Timothy Perera, Martijn Paul Lolkema
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. The oncologist (2023)
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for immunotherapy of cancer 10 (10) (2022)
D Ross Camidge, Fabrice Barlesi, Jonathan Wade Goldman, Daniel Morgensztern, Rebecca S Heist, Everett E Vokes, Alexander I Spira, Eric Angevin, Wu-Chou Su, David S Hong, John H Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)